医薬品のアメリカ市場

◆英語タイトル:Pharmaceuticals in the United States
◆商品コード:MLINE7081758
◆発行会社(リサーチ会社):MarketLine
◆発行日:2017年6月30日
◆ページ数:39
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD350 ⇒換算¥39,550見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD700 ⇒換算¥79,100見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD1,050 ⇒換算¥118,650見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketLine社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。MarketLine社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Pharmaceuticals in the United States
Summary

Pharmaceuticals in the United States industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the United States pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2016 annual average exchange rates.
- The US pharmaceuticals market had total revenues of $377.0bn in 2016, representing a compound annual growth rate (CAGR) of 7% between 2012 and 2016.
- High consumption and prices in the United States continues to propel growth in the market. Price inflation, to the discontent of the wider public, has helped this.
- The US is the world’s largest pharmaceuticals market and maintains consistently good growth despite its already highly developed nature and due to the very strong private health sector. The country also has more patents, R&D development facilities, industry employment and major global companies than any other market.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in the United States
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in the United States
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the United States pharmaceuticals market with five year forecasts

Reasons to buy

- What was the size of the United States pharmaceuticals market by value in 2016?
- What will be the size of the United States pharmaceuticals market in 2021?
- What factors are affecting the strength of competition in the United States pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitiors in the United States’s pharmaceuticals market?

【レポートの目次】

Table of Contents
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
AstraZeneca PLC
Johnson & Johnson
Merck & Co., Inc.
Pfizer Inc.
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

List of Tables
Table 1: United States pharmaceuticals market value: $ billion, 2012–16
Table 2: United States pharmaceuticals market geography segmentation: $ billion, 2016
Table 3: United States pharmaceuticals market share: % share, by value, 2016
Table 4: United States pharmaceuticals market value forecast: $ billion, 2016–21
Table 5: AstraZeneca PLC: key facts
Table 6: AstraZeneca PLC: key financials ($)
Table 7: AstraZeneca PLC: key financial ratios
Table 8: Johnson & Johnson: key facts
Table 9: Johnson & Johnson: key financials ($)
Table 10: Johnson & Johnson: key financial ratios
Table 11: Merck & Co., Inc.: key facts
Table 12: Merck & Co., Inc.: key financials ($)
Table 13: Merck & Co., Inc.: key financial ratios
Table 14: Pfizer Inc.: key facts
Table 15: Pfizer Inc.: key financials ($)
Table 16: Pfizer Inc.: key financial ratios
Table 17: United States size of population (million), 2012–16
Table 18: United States gdp (constant 2005 prices, $ billion), 2012–16
Table 19: United States gdp (current prices, $ billion), 2012–16
Table 20: United States inflation, 2012–16
Table 21: United States consumer price index (absolute), 2012–16
Table 22: United States exchange rate, 2012–15

List of Figures
Figure 1: United States pharmaceuticals market value: $ billion, 2012–16
Figure 2: United States pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 3: United States pharmaceuticals market share: % share, by value, 2016
Figure 4: United States pharmaceuticals market value forecast: $ billion, 2016–21
Figure 5: Forces driving competition in the pharmaceuticals market in the United States, 2016
Figure 6: Drivers of buyer power in the pharmaceuticals market in the United States, 2016
Figure 7: Drivers of supplier power in the pharmaceuticals market in the United States, 2016
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2016
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2016
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2016
Figure 11: AstraZeneca PLC: revenues & profitability
Figure 12: AstraZeneca PLC: assets & liabilities
Figure 13: Johnson & Johnson: revenues & profitability
Figure 14: Johnson & Johnson: assets & liabilities
Figure 15: Merck & Co., Inc.: revenues & profitability
Figure 16: Merck & Co., Inc.: assets & liabilities
Figure 17: Pfizer Inc.: revenues & profitability
Figure 18: Pfizer Inc.: assets & liabilities

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 医薬品のアメリカ市場(Pharmaceuticals in the United States)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆